Design, synthesis, and structure-activity relationships of the first highly potent, selective, and bioavailable adenosine 5'-monophosphate deaminase inhibitors.

Kasibhatla, S R; Bookser, B C; Appleman, J R; Probst, G; Xiao, W; Fujitaki, J M; Erion, M D

Kasibhatla, S R; Bookser, B C; Appleman, J R; Probst, G; Xiao, W; Fujitaki, J M; Erion, M D.

Affiliation

Kasibhatla SR; Metabasis Therapeutics Inc., San Diego, California 92121, USA.

Adv Exp Med Biol ; 431: 849-52, 1998.

Article in En | MEDLINE | ID: mdl-9598183

Subject(s)

AMP Deaminase/antagonists & inhibitors; Adenine/analogs & derivatives; Adenine/chemistry; Coformycin/analogs & derivatives; Coformycin/chemistry; Enzyme Inhibitors/chemistry; Adenine/chemical synthesis; Adenine/pharmacokinetics; Adenosine Monophosphate/chemistry; Administration, Oral; Biological Availability; Coformycin/chemical synthesis; Coformycin/pharmacokinetics; Drug Design; Entropy; Enzyme Inhibitors/chemical synthesis; Enzyme Inhibitors/pharmacokinetics; Humans; Models, Molecular; Molecular Conformation; Molecular Structure; Structure-Activity Relationship

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Adenine / Coformycin / Enzyme Inhibitors / AMP Deaminase Limits: Humans Language: En Journal: Adv Exp Med Biol Year: 1998 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links